A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.
(2005) Cancer Immunology, Immunotherapy : other biological response modifications — Vol. 54, n° 12, p. 1214-1220 (2005)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 292.39 KB
Details
- Authors
- Abstract
- "Cancer-germline" genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in normal tissues. They encode shared tumor-specific antigens that have been used in therapeutic vaccination trials of cancer patients. It was previously demonstrated that MAGE-1 peptide KVLEYVIKV was presented by HLA-A 0201 molecules on the surface of a human breast carcinoma cell line, but no human specific CTL had been isolated so far. Here, we have used HLA-A2/MAGE-1 fluorescent multimers to isolate from blood cells three human CTL clones that recognized the MAGE-1 peptide. These clones killed efficiently HLA-A2 tumor cells expressing MAGE-1, whether or not they were treated with IFN-gamma, suggesting that the MAGE-1 antigen is processed efficiently by both the standard proteasome and the immunoproteasome. These results indicate that the MAGE-1.A2 peptide can be used for antitumoral vaccination.
- Affiliations
Citations
Ottaviani, S., Zhang, Y., Boon, T., & van der Bruggen, P. (2005). A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunology, Immunotherapy : other biological response modifications, 54(12), 1214-1220. https://doi.org/10.1007/s00262-005-0705-2 (Original work published 2005)